1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Germany >
  5. BioNTech Acquires CureVac

M&A Deal Summary

BioNTech Acquires CureVac

On June 12, 2025, BioNTech acquired life science company CureVac for 1.3B USD

Acquisition Highlights
  • This is BioNTech’s 5th transaction in the Life Science sector.
  • This is BioNTech’s largest (disclosed) transaction.
  • This is BioNTech’s 2nd transaction in Germany.

M&A Deal Summary
Date 2025-06-12
Target CureVac
Sector Life Science
Buyer(s) BioNTech
Deal Type Add-on Acquisition
Deal Value 1.3B USD
Advisor(s) Goldman Sachs (Financial)
Skadden, Arps, Slate, Meagher & Flom
NautaDutilh (Legal)

Target

CureVac

Tuebingen, Germany
CureVac is a multinational biotech company that advances the field of messenger RNA (mRNA) technology for application in human medicine. The company's mRNA platform incorporates a series of novel technologies, designed to improve the efficacy, safety and cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced immune responses at lower doses. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that aim to enable the human body to produce its own therapeutic proteins. Formed in 2000, CureVac is headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

BioNTech

Mainz, Germany
Category Company
Founded 2008
Sector Life Science
Employees6,133
Revenue 2.8B EUR (2024)
DESCRIPTION

BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech founded in 2008 and is based in Mainz, Germany.

DEAL STATS #
Overall 6 of 6
Sector: Life Science M&A 5 of 5
Type: Add-on Acquisition M&A Deals 4 of 4
Country: Germany M&A 2 of 2
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-11-13 Biotheus

Zhuhai, China

Biotheus is a clinical development stage company with the mission of treating cancer and autoimmune diseases through next-generation therapeutics. Biotheus was founded in 2018 and is based in Zhuhai, China.

Buy $800M
Mergr

Solution for

Product

Company

Legal